Opioid Receptor Antagonists- Pipeline Insight, 2018

  • ID: 4471028
  • Drug Pipelines
  • 99 pages
  • DelveInsight
1 of 4

FEATURED COMPANIES

  • Adolor Corporation
  • BlackThorn Therapeutics
  • Elorac
  • Janssen Pharmaceuticals
  • Merck
  • OrphoMed
  • MORE
"Opioid Receptor Antagonists- Pipeline Insight, 2018" report outlays comprehensive Insight of present scenario and growth prospects across Opioid Receptor Antagonists. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 30+ products along with 20+ companies involved.

Products covered by Phase
  • Phase III, Phase II and Phase I
  • Pre-clinical and Discovery
  • Inactive (Dormant and Discontinued)
Overview of pipeline development activities for Opioid Receptor Antagonists

Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.

Therapeutic segmentation of products for Opioid Receptor Antagonists

The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this mechanism.

Methodology

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by a team of industry experts.

Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
  • Provides an overview of therapeutic pipeline activity for Opioid Receptor Antagonists across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of Opioid Receptor Antagonists therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across Opioid Receptor Antagonists
Reasons to Buy
  • Establish a comprehensive understanding of the current pipeline scenario across Opioid Receptor Antagonists to formulate effective R&D strategies
  • Assess challenges and opportunities that influence Opioid Receptor Antagonists R&D
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify the relationship between the products and use it for target finding, drug repurposing, and precision medicine
  • Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Opioid Receptor Antagonists to enhance and expand business potential and scope
  • Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive drugs
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Adolor Corporation
  • BlackThorn Therapeutics
  • Elorac
  • Janssen Pharmaceuticals
  • Merck
  • OrphoMed
  • MORE
Executive Summary
Overview
Opioids
Types of Opioid Receptors
Opioid Receptor Antagonists in Dermatology
Opioid Receptor Antagonists in Gastrointestinal Diseases
Opioid Receptor Antagonists in Central Nervous System
Pipeline Therapeutics (Active Products)
Pipeline Therapeutics (Inactive Products)
Comparative Analysis
Late Stage Products (Filed & Phase III)
Comparative Analysis
CAM2038: Camurus
Product Description
Research and Development
Product Development Activities
Upcoming Milestones
(The list continues)
Mid-Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I)
Comparative Analysis
Pre-Clinical & Discovery Stage Products
Comparative Analysis
Therapeutic Assessment: Active Products
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Dormant & Discontinued Products
Comparative Analysis
Appendix

List of Tables:
Table 1: Total Products for Opioid Receptor Antagonists
Table 2: Late Stage Products (Filed & Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-Clinical & Discovery Stage Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Dormant Products
Table 11: Discontinued Products

List of Figures:
Figure 1: Opioid Receptor Signaling
Figure 2: Total Products for Opioid Receptor Antagonists
Figure 3: Late Stage Products (Filed & Phase III)
Figure 4: Mid Stage Products (Phase II)
Figure 5: Early Stage Products (Phase I)
Figure 6: Pre-Clinical & Discovery Stage Products
Figure 7: Assessment by Monotherapy Products
Figure 8: Assessment by Combination Products
Figure 9: Assessment by Route of Administration
Figure 10: Assessment by Stage and Route of Administration
Figure 11: Dormant & Discontinued Products
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Adolor Corporation
  • Alkermes
  • Astraea Therapeutics
  • BlackThorn Therapeutics
  • Camurus
  • Eli Lilly
  • Elorac
  • GlaxoSmithKline
  • INSYS Therapeutics
  • Janssen Pharmaceuticals
  • Japan Tobacco
  • Kyorin Pharmaceuticals
  • Merck
  • Merck/Banyu
  • Opiant Pharmaceuticals
  • OrphoMed
  • Pfizer
  • RTI International
  • SRI International
  • TaiwanJ Pharmaceuticals
  • Theravance Biopharma
  • Trevi Therapeutics
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll